{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-051576","form_type":"8-K","ticker":"ACRV","cik":"0001781174","company_name":"Acrivon Therapeutics, Inc.","filed_at":"2025-04-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.687001+00:00","generated_at":"2026-05-23T19:49:05.576834+00:00","sec_items":["7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Acrivon Therapeutics appoints Mansoor Raza Mirza as CMO effective April 9, 2025","bullets":["Dr. Mirza is a gynecologic oncology KOL who led registrational trials for Zejula (PARP inhibitor) and frontline endometrial cancer therapy.","Current CMO Jean-Marie Cuillerot departs on April 9, 2025.","Dr. Mirza will lead Phase 2b trial of ACR-368 for endometrial cancer and Phase 1 trial of ACR-2316.","He previously served as chief oncologist at Copenhagen University Hospital and medical director of NSGO CTU."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-051576","json":"https://secwatch.observer/filing/0000950170-25-051576.json","markdown":"https://secwatch.observer/filing/0000950170-25-051576.md","text":"https://secwatch.observer/filing/0000950170-25-051576.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1781174/000095017025051576/0000950170-25-051576-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1781174/000095017025051576/acrv-20250407.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T19:49:05.576834+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}